Ontology highlight
ABSTRACT:
SUBMITTER: Molina-Guijarro JM
PROVIDER: S-EPMC3083409 | biostudies-literature | 2011 Apr
REPOSITORIES: biostudies-literature
PloS one 20110427 4
Irvalec is a marine-derived antitumor agent currently undergoing phase II clinical trials. In vitro, Irvalec induces a rapid loss of membrane integrity in tumor cells, accompanied of a significant Ca(2+) influx, perturbations of membrane conductivity, severe swelling and the formation of giant membranous vesicles. All these effects are not observed in Irvalec-resistant cells, or are significantly delayed by pretreating the cells with Zn(2+). Using fluorescent derivatives of Irvalec it was demons ...[more]